Date: 2014-06-18
Type of
information: Presentation of results at a congress
phase: 1
Announcement: presentation of results at the joint Meeting of the European and International Societies of Hypertension (ESH-ISH) in Athens (Greece)
Company: Quantum Genomics (France)
Product: QGC001
Action
mechanism:
- enzyme inhibitor/Brain Aminopeptidase A inhibitor (BAPAI). QGC001 is a Brain Aminopeptidase A inhibitor (BAPAI) product. This candidate is a prodrug that delivers in the brain the EC33 product, a selective and specific inhibitor of Aminopeptidase A, thus preventing the production of Angiontensin III in the brain. Several preclinical studies and two clinical studies have been conducted already using QGC001 to assess its pharmacokinetic, pharmacodynamic, safety and tolerance parameters in animals and humans. In 2014, Quantum Genomics intends to pursue the clinical development of QGC001 by initiating a phase IIa study to evaluate its effectiveness in hypertensive patients.
Disease: hypertension
Therapeutic
area: Cardiovascular diseases
Country:
Trial
details:
Latest
news:
- • On June 18, 2014, Quantum Genomics disclosed the final results of phase I clinical trials for QGC001 during the joint Meeting of the European and International Societies of Hypertension (ESH-ISH) in Athens (Greece). The achieved positive results, especially in terms of tolerance and safety profile, allow to start a Phase II clinical trial in hypertensive patients.
Is
general: Yes
